A Walgreens study sheds light on the benefits of patient-centered pharmacy-based programs.
The call for antimicrobial stewardship is growing. Enact these steps to prevent a return to the pre-antibiotic era.
Here are five critical regulations that executives can begin to prepare for today.
Report highlights spending trends in key areas, including specialty medications, oncology, diabetes, and inflammatory conditions.
Alcohol and drug dependency treatment goals can tied to an insurer’s pay-for-performance incentive program. Here’s how.
As part of efforts to combat the opioid epidemic, Cigna removes prior authorization from medication-assisted treatment for opioid use disorder.
Biosimilars in the United States are slowly gaining traction, but widespread confusion and legal barriers remain.
Biomarkers, if used appropriately, could ensure patients receive the appropriate treatment sooner, and that they have better outcomes at reduced costs. But despite the potential and expanding capabilities, barriers to full-fledged use remain.
As the opioid epidemic continues across the U.S., new treatment programs and guidelines could help reverse the trend.
When is retail right? Consider these four benefits that will impact the bottom line.